- Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
[作者:Lee, EC; Fitzgerald, M; Bannerman, B; Donelan, J; Bano, K; Terkelsen, J; Bradley, DP; Subakan, O; Silva, MD; Liu, R; Pickard, M; Li, Z; Tayber, O; Li, P; Hales, P; Carsillo, M; Neppalli, VT; Berger, AJ; Kupperman, E; Manfredi, M; Bolen, JB; Van Ness, B; Janz, S,期刊:Clinical Cancer Research, 页码:7313-7323 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhi...
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
[作者:Gotink, KJ; Broxterman, HJ; Labots, M; de Haas, RR; Dekker, H; Honeywell, RJ; Rudek, MA; Beerepoot, LV; Musters, RJ; Jansen, G; Griffioen, AW; Assaraf, YG; Pili, R; Peters, GJ; Verheul, HMW,期刊:Clinical Cancer Research, 页码:7337-7346 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an important clinical problem, but its underlying mechanisms are largely unknown. We analyzed tumor sunitinib levels in mice and patie...
- Gene Expression Differences between Colon and Rectum Tumors
[作者:Sanz-Pamplona, R; Cordero, D; Berenguer, A; Lejbkowicz, F; Rennert, H; Salazar, R; Biondo, S; Sanjuan, X; Pujana, MA; Rozek, L; Giordano, TJ; Ben-Izhak, O; Cohen, HI; Trougouboff, P; Bejhar, J; Sova, Y; Rennert, G; Gruber, SB; Moreno, V,期刊:Clinical Cancer Research, 页码:7303-7312 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: Colorectal cancer studies typically include both colon and rectum tumors as a common entity, though this assumption is controversial and only minor differences have been reported at the molecular and epidemiolog...
- CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients
[作者:Iacobucci, I; Ferrari, A; Lonetti, A; Papayannidis, C; Paoloni, F; Trino, S; Storlazzi, CT; Ottaviani, E; Cattina, F; Impera, L; Abbenante, MC; Vignetti, M; Vitale, A; Potenza, L; Paolini, S; Soverini, S; Pane, F; Luppi, M; Foa, R; Baccarani, M; Martinelli, G,期刊:Clinical Cancer Research, 页码:7413-7423 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: The 9p21 locus, encoding three important tumor suppressors (p16/CDKN2A, p14/ARF, and p15/CDKN2B), is a major target of inactivation in the pathogenesis of many human tumors.Patients and Methods: To explore, at h...
- Molecular Imaging of TGF beta-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGF beta Signaling
[作者:Nyati, S; Schinske, K; Ray, D; Nyati, M; Ross, BD; Rehemtulla, A,期刊:Clinical Cancer Research, 页码:7424-7439 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: The dual modality of TGF beta, both as a potent tumor suppressor and a stimulator of tumor progression, invasion, and metastasis, make it a critical target for therapeutic intervention in human cancers. The abil...
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
[作者:Fiskus, W; Verstovsek, S; Manshouri, T; Rao, R; Balusu, R; Venkannagari, S; Nalabothula, NR; Ha, K; Smith, JE; Hembruff, SL; Abhyankar, S; McGuirk, J; Bhalla, KN,期刊:Clinical Cancer Research, 页码:7347-7358 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: We determined the activity of hsp90 inhibitor, and/or Janus-activated kinase 2 (JAK2) tyrosine kinase inhibitor (TKI), against JAK2-V617F-expressing cultured mouse (Ba/F3-JAK2-V617F) and human (HEL92.1.7 and UKE...
- Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
[作者:Park, SI; Shenoi, J; Frayo, SM; Hamlin, DK; Lin, YK; Wilbur, DS; Stayton, PS; Orgun, N; Hylarides, M; Buchegger, F; Kenoyer, AL; Axtman, A; Gopal, AK; Green, DJ; Pagel, JM; Press, OW,期刊:Clinical Cancer Research, 页码:7373-7382 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, "endogenous" biotin can interfere ...
- Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma
[作者:Weiss, GR; Grosh, WW; Chianese-Bullock, KA; Zhao, YD; Liu, H; Slingluff, CL; Marincola, FM; Wang, E,期刊:Clinical Cancer Research, 页码:7440-7450 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: We have previously shown that within tumors, recombinant interleukin-2 (rIL-2, aldesleukin) consistently activates tumor-associated macrophages and upregulates IFN-stimulated genes while inducing minimal migrati...
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
[作者:Kim, KB; Chesney, J; Robinson, D; Gardner, H; Shi, MM; Kirkwood, JM,期刊:Clinical Cancer Research, 页码:7451-7461 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor (FGF), VEGF, and platelet-derived growth factor receptors. This phase I/II dose-escalation study was conducted to evaluate the safe...
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
[作者:Fruehauf, J; Lutzky, J; McDermott, D; Brown, CK; Meric, JB; Rosbrook, B; Shalinsky, DR; Liau, KF; Niethammer, AG; Kim, S; Rixe, O,期刊:Clinical Cancer Research, 页码:7462-7469 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, ...
- Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
[作者:Cheema, TA; Kanai, R; Kim, GW; Wakimoto, H; Passer, B; Rabkin, SD; Martuza, RL,期刊:Clinical Cancer Research, 页码:7383-7393 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: Glioblastoma (GBM) inevitably recurs despite surgery, radiation, and chemotherapy. A subpopulation of tumor cells, GBM stem cells (GSC), has been implicated in this recurrence. The chemotherapeutic agent etoposi...
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
[作者:Heuckmann, JM; Holzel, M; Sos, ML; Heynck, S; Balke-Want, H; Koker, M; Peifer, M; Weiss, J; Lovly, CM; Grutter, C; Rauh, D; Pao, W; Thomas, RK,期刊:Clinical Cancer Research, 页码:7394-7401 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: EML4-ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance...
- The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
[作者:Agnelli, L; Forcato, M; Ferrari, F; Tuana, G; Todoerti, K; Walker, BA; Morgan, GJ; Lombardi, L; Bicciato, S; Neri, A,期刊:Clinical Cancer Research, 页码:7402-7412 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: The combined use of microarray technologies and bioinformatics analysis has improved our understanding of biological complexity of multiple myeloma (MM). In contrast, the application of the same technology in th...
- Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
[作者:Zaanan, A; Flejou, JF; Emile, JF; Des Guetz, G; Cuilliere-Dartigues, P; Malka, D; Lecaille, C; Validire, P; Louvet, C; Rougier, P; de Gramont, A; Bonnetain, F; Praz, F; Taieb, J,期刊:Clinical Cancer Research, 页码:7470-7478 , 文章类型: Article,,卷期:2011年17-23]
- Purpose: Adding oxaliplatin to adjuvant 5-fluorouracil (5-FU) chemotherapy improves 3-year disease-free survival (DFS) after resection of stage III colon cancer. Several studies suggest that patients with tumors exhibiti...
|